Information Provided By:
Fly News Breaks for February 27, 2020
Feb 27, 2020 | 09:01 EDT
Raymond James analyst Steven Seedhouse lowered the firm's price target on Editas Medicine to $41 from $44 and keeps an Outperform rating on the shares following the company's Q4 results. Most incremental in its update, Seedhouse says Editas remains on track to dose the first patient in Phase 1/2 study of EDIT-101 in LCA10 in 1Q20 and remains on track to submit the IND for EDIT-301 by YE20 in sickle-cell disease.
News For EDIT From the Last 2 Days
There are no results for your query EDIT